| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Chun-Yen Chen, Yi-Wei Yeh, Shin-Chang Kuo, Pei-Shen Ho, Chih-Sung Liang, Che-Hung Yen, Ru-Band Lu, San-Yuan Huan. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology. vol 65. 2016-12-13. PMID:26724569. |
a 12-week naturalistic study of amisulpride treatment was carried out in 185 han chinese patients with schizophrenia. |
2016-12-13 |
2023-08-13 |
human |
| Chun-Yen Chen, Yi-Wei Yeh, Shin-Chang Kuo, Pei-Shen Ho, Chih-Sung Liang, Che-Hung Yen, Ru-Band Lu, San-Yuan Huan. Catechol-O-methyltransferase gene variants may associate with negative symptom response and plasma concentrations of prolactin in schizophrenia after amisulpride treatment. Psychoneuroendocrinology. vol 65. 2016-12-13. PMID:26724569. |
our results suggest that variation of the comt gene is associated with treatment response regarding negative symptoms and prolactin changes after amisulpride treatment in patients with schizophrenia. |
2016-12-13 |
2023-08-13 |
human |
| James E Hotham, Patrick J D Simpson, Rosalie S Brooman-White, Amlan Basu, Callum C Ross, Sharon A Humphreys, Fintan Larkin, Nitin Gupta, Mrigendra Da. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS spectrums. vol 19. issue 5. 2016-07-21. PMID:24284256. |
augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a uk high-security hospital. |
2016-07-21 |
2023-08-12 |
Not clear |
| James E Hotham, Patrick J D Simpson, Rosalie S Brooman-White, Amlan Basu, Callum C Ross, Sharon A Humphreys, Fintan Larkin, Nitin Gupta, Mrigendra Da. Augmentation of clozapine with amisulpride: an effective therapeutic strategy for violent treatment-resistant schizophrenia patients in a UK high-security hospital. CNS spectrums. vol 19. issue 5. 2016-07-21. PMID:24284256. |
here we present a case series of 6 schizophrenia patients, within a high-security hospital, who have a history of serious violence and who were treated with clozapine augmented with amisulpride. |
2016-07-21 |
2023-08-12 |
Not clear |
| Li-Chung Huang, Li-Yen Huang, Shih-Yen Tseng, Yuh-Ming Hou, Cheng-Cheng Hsia. Amisulpride and symptomatic bradycardia: a case report. General hospital psychiatry. vol 37. issue 5. 2016-07-14. PMID:26162544. |
amisulpride is a second-generation antipsychotic agent indicated for the treatment of schizophrenia and other major psychotic illnesses. |
2016-07-14 |
2023-08-13 |
Not clear |
| Ying Liang, Yun-Ai Su, Zhen-Guo Zhao, Nan Gao, Ji-Zhong Huang, Mao-Qin Tang, Ke-Qing Li, Fu-De Yang, Xin Yu, Tian-Mei S. Acute Effects of Haloperidol, Amisulpride, and Quetiapine on Bone Turnover Markers in Patients With Schizophrenia. Journal of clinical psychopharmacology. vol 35. issue 5. 2016-06-01. PMID:26270200. |
acute effects of haloperidol, amisulpride, and quetiapine on bone turnover markers in patients with schizophrenia. |
2016-06-01 |
2023-08-13 |
Not clear |
| Vasiliki Dimitrakopoulou, Orestis Efthimiou, Stefan Leucht, Georgia Salant. Accounting for uncertainty due to 'last observation carried forward' outcome imputation in a meta-analysis model. Statistics in medicine. vol 34. issue 5. 2016-04-22. PMID:25492741. |
we illustrate our methods by performing a meta-analysis of five studies comparing the efficacy of amisulpride versus conventional drugs (flupenthixol and haloperidol) on patients diagnosed with schizophrenia. |
2016-04-22 |
2023-08-13 |
human |
| Seung-Gul Kang, Kyoung-Sae Na, Heon-Jeong Lee, Ik-Seung Chee, Kwanghun Lee, Jonghun Le. DRD2 genotypic and haplotype variation is associated with improvements in negative symptoms after 6 weeks' amisulpride treatment. Journal of clinical psychopharmacology. vol 35. issue 2. 2015-12-21. PMID:25679126. |
after 6 weeks of treatment with amisulpride, 125 schizophrenia patients were interviewed based on the positive and negative syndrome scale and the clinical global impression-severity scale. |
2015-12-21 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Kristof Vansteelandt, Agnieszka Remlinger-Molenda, W Wolfgang Fleischhacker, René S Kahn, Joseph Peusken. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25085534. |
the european first episode schizophrenia trial (eufest) included first-episode schizophrenia patients, assessing the efficacy of five antipsychotic drugs (haloperidol, amisulpride, olanzapine, quetiapine and ziprasidone) over one year. |
2015-11-02 |
2023-08-13 |
Not clear |
| Janusz K Rybakowski, Kristof Vansteelandt, Agnieszka Remlinger-Molenda, W Wolfgang Fleischhacker, René S Kahn, Joseph Peusken. Extrapyramidal symptoms during treatment of first schizophrenia episode: results from EUFEST. European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology. vol 24. issue 9. 2015-11-02. PMID:25085534. |
the results obtained suggest that in first-episode schizophrenia patients during the first year of antipsychotic treatment (in this case amisulpride, haloperidol in low doses, olanzapine, quetiapine and ziprasidone), eps were present as manageable clinical problems. |
2015-11-02 |
2023-08-13 |
Not clear |
| Shani Pridan, Yehuda Baruch, Marnina Swartz, Yoram Bara. Amisulpride for older patients with long-standing schizophrenia. Journal of clinical psychopharmacology. vol 34. issue 6. 2015-07-28. PMID:25275673. |
amisulpride for older patients with long-standing schizophrenia. |
2015-07-28 |
2023-08-13 |
Not clear |
| Shani Pridan, Yehuda Baruch, Marnina Swartz, Yoram Bara. Amisulpride for older patients with long-standing schizophrenia. Journal of clinical psychopharmacology. vol 34. issue 6. 2015-07-28. PMID:25275673. |
the present study was designed to evaluate the efficacy and safety of amisulpride monotherapy in a diagnostically homogeneous group of elderly patients without cognitive impairment experiencing schizophrenia (diagnostic and statistical manual of mental disorders, fourth edition, text revision criteria for schizophrenia). |
2015-07-28 |
2023-08-13 |
Not clear |
| Shani Pridan, Yehuda Baruch, Marnina Swartz, Yoram Bara. Amisulpride for older patients with long-standing schizophrenia. Journal of clinical psychopharmacology. vol 34. issue 6. 2015-07-28. PMID:25275673. |
of the 527 elderly schizophrenia patients for a 5-year period (2007-2013), 30 patients, mean (sd) age of 67.5 (5.8) years, were treated with amisulpride monotherapy. |
2015-07-28 |
2023-08-13 |
Not clear |
| Shani Pridan, Yehuda Baruch, Marnina Swartz, Yoram Bara. Amisulpride for older patients with long-standing schizophrenia. Journal of clinical psychopharmacology. vol 34. issue 6. 2015-07-28. PMID:25275673. |
we tentatively conclude that our preliminary results demonstrate that amisulpride is an efficacious and safe atypical antipsychotic for the treatment for elderly schizophrenia patients. |
2015-07-28 |
2023-08-13 |
Not clear |
| Wei-Chen Chuang, Chun-Yen Chen, Shin-Chang Kuo, Tien-Yu Chen, Yi-Wei Ye. Amisulpride-associated mania in a young adult with schizophrenia and cerebral disease. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. vol 71. issue 23. 2015-07-20. PMID:25404595. |
a case of rapid-onset mania after initiating amisulpride in a patient with schizophrenia and cerebral disease is reported. |
2015-07-20 |
2023-08-13 |
Not clear |
| Signe Düring, Birte Y Glenthøj, Gitte Saltoft Andersen, Bob Oranj. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 13. 2015-07-07. PMID:24954063. |
in the present study, the effects of a potent d2/d3 receptor antagonist, amisulpride, were investigated on ppi and p50 gating in a large sample of antipsychotic-naive, first-episode patients with schizophrenia. |
2015-07-07 |
2023-08-13 |
human |
| Signe Düring, Birte Y Glenthøj, Gitte Saltoft Andersen, Bob Oranj. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 13. 2015-07-07. PMID:24954063. |
a total of 52 initially antipsychotic-naive, first-episode schizophrenia patients were assessed for their p50 gating, ppi, and habituation/sensitization abilities at baseline and after 2 and 6 weeks of treatment with flexible doses of amisulpride. |
2015-07-07 |
2023-08-13 |
human |
| Signe Düring, Birte Y Glenthøj, Gitte Saltoft Andersen, Bob Oranj. Effects of dopamine D2/D3 blockade on human sensory and sensorimotor gating in initially antipsychotic-naive, first-episode schizophrenia patients. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology. vol 39. issue 13. 2015-07-07. PMID:24954063. |
this is the first study investigating the effects of monotherapy with a relatively selective dopamine d2/d3 receptor antagonist (amisulpride) on sensory and sensorimotor gating deficits in a longitudinal study of a large group of initially antipsychotic-naive, first-episode patients with schizophrenia. |
2015-07-07 |
2023-08-13 |
human |
| Fabiani Bogorni, Frederico Fernandes Moreira, Eduardo Mylius Pimentel, Géder Evandro Motta Grohs, Alexandre Paim Dia. Amisulpride augmentation for clozapine-refractory positive symptoms: additional benefit in reducing hypersialorrhea. Case reports in psychiatry. vol 2015. 2015-04-03. PMID:25838958. |
this is a case of a 30-year-old male with refractory schizophrenia; in this patient, the remission of residual positive symptoms, as well as the reduction of cih, was achieved by treatment with clozapine augmented with amisulpride. |
2015-04-03 |
2023-08-13 |
Not clear |
| Stephen Z Levine, Stefan Leuch. Treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. Schizophrenia research. vol 156. issue 1. 2014-12-22. PMID:24794879. |
treatment response heterogeneity in the predominant negative symptoms of schizophrenia: analysis of amisulpride vs placebo in three clinical trials. |
2014-12-22 |
2023-08-13 |
Not clear |